November 18, 2026
Health news, explained with evidence
LIVE
CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee

Study Finds Current Vaccines Neutralize Emerging SARS-CoV-2 Variant PJ.2.1

🧠 AI Analysis 2 min read 👁 4

Recent laboratory research indicates that antibodies from updated COVID-19 boosters effectively neutralize the new PJ.2.1 variant, despite its enhanced ability to bind to human cells.

Study Finds Current Vaccines Neutralize Emerging SARS-CoV-2 Variant PJ.2.1🧠AI Analysis

Photo: Medical Xpress

Key points

  • PJ.2.1 is an emerging saltation variant exhibiting stronger binding to the ACE2 cellular receptor.
  • Laboratory tests show that antibodies from the current XFG-adapted vaccine effectively neutralize the variant.
  • Researchers found no evidence that PJ.2.1 causes more severe illness or different symptoms than prior strains.

A new SARS-CoV-2 variant designated PJ.2.1, which has been spreading internationally since May, remains vulnerable to antibodies generated by the current booster vaccine, according to a recent study conducted by researchers at the German Primate Center and Hannover Medical School. The findings, published in scientific journals including the Journal of Infection and The Lancet Infectious Diseases, offer reassuring data amid high infection numbers in Europe and North America.

The research team, led by infection biologists Markus Hoffmann and Stefan Pöhlmann alongside Georg Behrens' group, investigated the biological characteristics of PJ.2.1. Their laboratory experiments revealed that the variant's spike protein binds more strongly to the ACE2 receptor compared to other studied strains, allowing it to more efficiently enter cells that express lower levels of this receptor. However, despite these enhanced cellular entry traits, tests showed that antibodies elicited by the XFG-adapted mRNA vaccine successfully inhibited the variant.

What to know: While the study suggests that current vaccination offers meaningful cross-protection against PJ.2.1, experts emphasize that virus evolution is ongoing, and future mutations could alter immune escape properties. The variant has been detected across various age groups, though current data shows no indication of elevated disease severity or novel clinical symptoms. Readers should consult a healthcare professional for guidance regarding personal vaccination choices.

Source Medical Xpress — medicalxpress.com/news/2026-11-sars-cov-variant-pj21-vaccine.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.